吴育晶，副教授

研究方向：抗炎免疫药理学、临床药理学

联系电话：65161206

电子邮箱：wyj@ahmu.edu.cn

办公室：103

教育经历：

(1) 1999-09至2003-07,复旦大学（原上海医科大学）,药学,学士；

(2) 2004-07至2007-07,复旦大学,药理学,硕士；

(3) 2012-09至2016-07,维多利亚老品牌vic3308,药理学,博士。

工作经历：

(1)2007.7~2009.7，维多利亚老品牌vic3308临床药理研究所，教学科研，助教；

(2)2009.8~2016.12，维多利亚老品牌vic3308临床药理研究所，教学科研，讲师；

(3)2018.9~2019.9，美国加州大学戴维斯分校，教学科研，访问学者；

(4)2016.12~2018.11，维多利亚老品牌vic3308临床药理研究所，教学科研，校聘副教授；

(5)2018.12~至今，维多利亚老品牌vic3308临床药理研究所，教学科研，副教授。

学术兼职：

(1)2021.7-至今 安徽省药理学会临床药理学专业委员会委员

(2) 2023.11-至今 安徽省药理学会抗炎免疫药理学专业委员会副秘书长

(3) 2023.12-至今 中国药理学会抗炎免疫药理学专业委员会青年委员会委员

科研工作：

长期从事类风湿关节炎（RA）病理机制、药物作用靶点、治疗药物的研究。主持IgD-Fc-Ig融合蛋白相关科研课题包括国家自然科学基金青年基金项目1项，安徽省自然科学青年基金1项，维多利亚老品牌vic3308博士科研资助基金优秀项目1项；参与多项国家自然科学基金面上项目、重点项目及安徽省科技攻关项目等。获得中国发明专利授权3项。

发表代表性论文情况：

[1]Wu Y#, Zhang A#, Chen W#, Xin Q, Pan W, Hu X, Li T, Chen H, Zhang J, Luan C, Ge J, Wei W*.IgD/FcδR is involved in T-cell acute lymphoblastic leukemia and regulated by IgD-Fc-Ig fusion protein. Pharmacol Res. 2023;4:106686. (1区，Top期刊)

[2] Chen Z, Xin Q, Wei W*,Wu Y*. The pathogenesis and development of targeted drugs in acute T lymphoblastic leukemia. Br J Pharmacol. 2023;180(8):1017-1037.  (1区，Top期刊)

[3] Pan W#, Xin Q#, Xu J, He J, Chen Z, Hu X, Li T, Zhu Y, Wei W*,Wu Y*. IgD enhances the release of neutrophil extracellular traps (NETs) via FcδR in rheumatoid arthritis patients. Int Immunopharmacol. 2023;114:109484.

[4] Liu D#, Hu X#, Chen Z, Wei W*,Wu Y*. Key links in the physiological regulation of the immune system and disease induction: T cell receptor-CD3 complex. Biochem Pharmacol. 2024;227:116441. (2区，Top期刊)

[5] Xin Q#, Chen Y, Sun X, Li R*,Wu Y*, Huang X*. CAR-T therapy for ovarian cancer: Recent advances and future directions. Biochem Pharmacol. 2024;226:116349. (2区，Top期刊)

[6] Feng X, Wang X, Liu J, Fu A, Wang Y, Wei S, Chen H, She R, Wang Y, Cui X, Hou H, Xu Y,Wu Y, Meng Q, Zhang L, Wang S, Zhao J. Accelerated Screening of Alternative DNA Base-Organic Molecule-Base Architectures via Integrated Theory and Experiment. Angew Chem Int Ed Engl. 2024;63(35):e202408003. (1区，Top期刊)

[7] Xin Q, Chen Z, Wei W*,Wu Y*. Animal models of acute lymphoblastic leukemia: Recapitulating the human disease to evaluate drug efficacy and discover therapeutic targets. Biochem Pharmacol. 2022;198:114970. (2区，Top期刊)

[8] Hu XX，Zhang AJ, Pan WW, Xin QL, Chen JY, Zhang LL, Chang Y,Wu YJ*, Wei W*. An IgD-Fc-Ig fusion protein restrains the activations of T and B cells via inhibiting IgD-IgDR-Lck signaling in rheumatoid arthritis. Acta Pharmacol Sin.  2022;43(2):387-400. (1区，Top期刊)

[9]Wu Y#, Pan W#, Hu X, Zhang A, Wei W*. The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis. Biochem Pharmacol. 2021;183:114360. (2区，Top期刊)

[10] Zhang J#, Hu XX#, Dong XJ, Chen WS, Zhang LL, Chang Y,Wu YJ*, Wei W*. Regulation of T cell activities in rheumatoid arthritis by the novel fusion protein IgD-Fc-Ig. Front Immunol. 2020; 11:755. (2区，Top期刊)

[11] Han L#, Zhang XZ#, Wang C, Tang XY, Zhu Y, Cai XY,Wu YJ, Shu JL, Wang QT, Chen JY, Chang Y, Wu HX, Zhang LL*, Wei W*. IgD-Fc-Ig fusion protein, a new biological agent, inhibits T cell function in CIA rats by inhibiting IgD-IgDR-Lck-NF-κB signaling pathways. Acta Pharmacol Sin. 2020;41(6):800-812. (1区，Top期刊)

[12] Hu XX#,Wu YJ#, Zhang J, Wei W*. T-cells interact with B cells, dendritic cells, and fibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis. Int Immunopharmacol. 2019;70:428-434.

[13] Dai X#, Wu YJ#, Jia XY, Chang Y, Wu HX, Wang C, Wei W*. Immunoglobulin D (IgD) and IgD receptor expression in diffuse large B-cell lymphoma. Hematology. 2019;24(1):544-551.

[14]Wu YJ#, Chen HS#, Chen WS, Dong J, Dong XJ, Dai X, Huang Q, Wei W*. CP-25 attenuates the activation of CD4 (+) T cells stimulated with immunoglobulin D in human. Front Pharmacol. 2018,9:4. (2区，Top期刊)

[15]Wu YJ#, Chen WS#, Chen HS, Dai X, Dong J, Wang Y, Zhang LL, Chang Y, Huang Q, Jia XY, Wei W*. The immunoglobulin D Fc receptor expressed on fibroblast-like synoviocytes from patients with rheumatoid arthritis contributes to the cell activation. Acta Pharmacol Sin. 2017;38(11)1466-1474. (1区，Top期刊)

[16] Wang QT,Wu YJ, Huang B, Ma YK, Song SS, Zhang LL, Chen JY, Wu HX, Sun WY, Wei W*. Etanercept attenuates collagen-induced arthritis by modulating the association between BAFFR expression and the production of splenic memory B cells. Pharmacol Res. 2013;68(1):38-45.   (1区，Top期刊)

[17] Chang Y#,Wu Y#, Wang D#, Wei W*, Qin Q, Xie G, Zhang L, Yan S, Chen J, Wang Q, Wu H, Xiao F, Sun W, Jin J, Wang W. Therapeutic effects of TACI-Ig on rats with adjuvant induced arthritis via attenuating inflammatory responses. Rheumatology (Oxford). 2011;50(5): 862-870.   (1区，Top期刊)